Evidence map›Paper›PMID 31881883›Full record

ArticleEnvironmental health : a global access science source2019

Intelligence gain and social cost savings attributable to environmental lead exposure reduction strategies since the year 2000 in Flanders, Belgium.

Sylvie Remy, Ramona Hambach, Marc Van Sprundel, Caroline Teughels, Tim S Nawrot, Jurgen Buekers, Christa Cornelis, Liesbeth Bruckers, Greet Schoeters

Open access · goldAbstract read
In one paragraph

Article in Environmental health : a global access science source, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Sylvie RemySustainable Health, Flemish Institute for Technological Research (VITO), Boeretang 200, 2400, Mol, Belgium. sylvie.remy@vito.be.ORCID 0000-0003-0322-9620
Ramona HambachOccupational Health Service Attentia Prevention & Protection, Keizer Karellaan 584, 1082, Brussels, Belgium.
Marc Van SprundelDepartment of Epidemiology and Social Medicine, University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium.
Caroline TeughelsVlaams Planbureau voor Omgeving, Koning Albert II laan 20, bus 8, Brussels, Belgium.
Tim S NawrotCentre for Environmental Sciences, Hasselt University, Agoralaan Gebouw D, 3590, Diepenbeek, Belgium.
Jurgen BuekersSustainable Health, Flemish Institute for Technological Research (VITO), Boeretang 200, 2400, Mol, Belgium.
Christa CornelisSustainable Health, Flemish Institute for Technological Research (VITO), Boeretang 200, 2400, Mol, Belgium.
Liesbeth BruckersI-BioStat, University of Hasselt, Agoralaan Gebouw D, 3590, Diepenbeek, Belgium.
Greet SchoetersSustainable Health, Flemish Institute for Technological Research (VITO), Boeretang 200, 2400, Mol, Belgium.
University of Antwerp · BEFlemish Institute for Technological Research · BEHasselt University · BEFederal Planning Bureau · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent lead (Pb) exposure reduction strategies enabled to lower children's blood lead levels (B-Pb) worldwide. This study reports the estimated intelligence gain and social cost savings attributable to recent exposure reduction based on reported B-Pb levels observed in adolescents sampled within the framework of the Flemish Environment and Health Studies (FLEHS, Belgium), i.e. in 2003-2004 (FLEHSI), in 2008-2009 (FLEHSII), and in 2013-2014 (FLEHSIII).

methodsIntelligence Quotient (IQ) loss per 100,000 individuals - attributable to B-Pb above 20 μg/L - was estimated based on widely accepted dose response functions between children's B-Pb and IQ (- 1.88 IQ points for a duplication in B-Pb from 20 μg/L onwards; 95% Confidence Interval (CI): - 1.16;-2.59) and B-Pb exposure distribution parameters of FLEHS studies. The results were translated to the Flemish population of 15-year-olds. Given a 3-year time gap between subsequent sampling periods, the exposure distribution of each study was assumed 3 years prior to the study as well. Economic impact was estimated based on expected decrease in lifetime earnings (€ 19,464 per decreasing IQ point in 2018).

resultsThe percentage of the adolescent population exceeding a B-Pb of 20 μg/L decreased from 57% (FLEHSI) to 23% (FLEHSII), and even further to 2.5% (FLEHSIII). The estimated IQ loss per 100,000 individuals was 94,280 (95% CI: 58,427-130,138) in FLEHSI, 14,993 (95% CI: 9289-20,695) in FLEHSII, and 976 (95% CI: 604-1347) in FLEHSIII. This translates into a total loss of 378,962 (95%CI: 234,840-523,091) IQ points within the Flemish population of 15-year-olds between 2000 and 2014. Assuming that current exposure levels do not reincrease, the expected IQ loss during the subsequent period of 15 years is estimated to be maximally 10,275 (95%CI: 6363-14,182) points.

conclusions7176 (95%CI: 4447-9905) million € of social cost savings were achieved by Pb reduction strategies in Flanders over 15 years. If current exposure levels further reduce to B-Pb below 20 μg/L for the whole population, social cost savings may increase up to 7376 (95%CI: 4571-10,181) million €. Given the relatively low lead contamination in Flanders, the global impact of ongoing reduction strategies is expected to be tremendous.

Indexed as

IntelligenceAdolescentBelgiumEnvironmental ExposureEnvironmental PollutantsEnvironmental PollutionFemaleHumansIntelligence TestsLeadMaleEnvironmental PollutantsLeadChemical exposure preventionHBMHuman biomonitoringIntelligence and economic gainLead exposure

Identifiers

PMID31881883
PMCPMC6935110
OpenAlexW2998672823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.